Kelly Darden
Adult Health · Beaumont, TXNPI 1629342951
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 619 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,830 and has fallen 87.3% since, to $360 in 2025. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 619 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- AstraZeneca$811
- Lilly USA, LLC$678
- Boehringer Ingelheim$627
- GSK$585
- plus $3K from 31 others
What the payments were for
- Food & beverage$10,109100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 152 | $2,158 |
| Novo Nordisk | 116 | $1,768 |
| AstraZeneca | 37 | $811 |
| Lilly USA, LLC | 48 | $678 |
| Boehringer Ingelheim | 34 | $627 |
| GSK | 31 | $585 |
| Pfizer | 31 | $546 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $514 |
| Amgen | 35 | $401 |
| Merck | 17 | $253 |
| Bayer | 11 | $231 |
| Kowa Pharmaceuticals America, Inc. | 11 | $179 |
| Corium, LLC | 9 | $173 |
| Johnson & Johnson | 9 | $150 |
| Novartis | 8 | $143 |
| Ironshore Pharmaceuticals Inc. | 7 | $139 |
| Abbott | 5 | $101 |
| Abiomed | 2 | $70 |
| Daiichi Sankyo Inc. | 3 | $66 |
| Esperion Therapeutics, Inc. | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Radius Health, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Astellas Pharma US Inc | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,116 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $125,503 |
| AustedoDeutetrabenazine | 13 | $95,660 |
| FarxigaDapagliflozin Propanediol | 80 | $59,891 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $41,758 |
| MounjaroTirzepatide | 40 | $40,848 |
| JardianceEmpagliflozin | 36 | $33,480 |
| EliquisApixaban | 27 | $32,963 |
| GlyxambiEmpagliflozin/Linagliptin | 40 | $26,989 |
| JanuviaSitagliptin Phosphate | 20 | $17,068 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $13,030 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $10,184 |
| MyrbetriqMirabegron | 14 | $8,094 |
| PremarinEstrogens, Conjugated | 24 | $7,408 |
| BelsomraSuvorexant | 12 | $5,364 |
| Rosuvastatin Calcium | 318 | $3,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,768 | $125,503105 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr | $627 | $70,65491 claims |
| AstraZenecaFarxiga | $811 | $59,89180 claims |
| GSKTrelegy Ellipta | $585 | $41,75842 claims |
| Lilly USA, LLCMounjaro | $678 | $40,84840 claims |
| PfizerEliquis, Premarin | $546 | $40,37151 claims |
| MerckJanuvia, Belsomra | $253 | $22,43132 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $8,09414 claims |
| AbbVieSynthroid | $2,158 | $1,04338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.
Other adult health in Beaumont
- Zeus ArcoBeaumont$17K
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Cynthia BedellPlano$168K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
- Meghan MurphyAustin$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.